↓ Skip to main content

Molecular targets for therapy in systemic sclerosis

Overview of attention for article published in Fibrogenesis & Tissue Repair, June 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

twitter
19 X users
facebook
1 Facebook page

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Molecular targets for therapy in systemic sclerosis
Published in
Fibrogenesis & Tissue Repair, June 2012
DOI 10.1186/1755-1536-5-s1-s19
Pubmed ID
Authors

Naoki Iwamoto, Oliver Distler

Abstract

Despite significant advances have been made in the recent years regarding organ-specific therapies, there is no approved 'disease-modifying' antifibrotic drug for systemic sclerosis (SSc) available to date. Although non-selective immunosuppressive agents are routinely used to treat patients with SSc, large well-controlled studies are lacking for almost all immunosuppressive agents and further evidence is required for long-term beneficial effects of these drugs. Considering these facts about immunosuppressive agents in SSc and also considering the high mortality of SSc, other therapeutic strategies are urgently needed. Recently an important role of the 5-hydroxytryptamine (5-HT: serotonin) pathway in fibrosis was reported. In this review, we discuss the role of 5-HT in fibrosis and therapeutic potential of this molecule. Besides 5-HT, there are a number of promising targets that have been extensively characterized in recent years. For many of these molecular targets, modifiers are readily available for clinical studies, and often these modifiers are used already in clinical use for other diseases. Results from these studies will show, in how far the promising preclinical results for novel antifibrotic strategies can be translated to clinical practice.

X Demographics

X Demographics

The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 35 97%

Demographic breakdown

Readers by professional status Count As %
Other 7 19%
Student > Master 6 17%
Student > Postgraduate 4 11%
Student > Ph. D. Student 3 8%
Student > Bachelor 3 8%
Other 5 14%
Unknown 8 22%
Readers by discipline Count As %
Medicine and Dentistry 15 42%
Agricultural and Biological Sciences 5 14%
Nursing and Health Professions 2 6%
Psychology 2 6%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 1 3%
Unknown 10 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2021.
All research outputs
#3,115,234
of 25,468,708 outputs
Outputs from Fibrogenesis & Tissue Repair
#8
of 86 outputs
Outputs of similar age
#19,939
of 181,003 outputs
Outputs of similar age from Fibrogenesis & Tissue Repair
#2
of 14 outputs
Altmetric has tracked 25,468,708 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 86 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 181,003 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.